HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAY 19-8004

a PDE4 inhibitor; structure in first source

Also Known As:

BAY-19-8004; BAY19-8004

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Inorganic Chemicals: 9
- Acids: 53217
  - Noncarboxylic Acids
    - Sulfur Acids
      - Sulfonic Acids: 1605
        BAY 19-8004: 1
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfonic Acids: 1605
      - BAY 19-8004: 1
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - BAY 19-8004: 1
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfonic Acids: 1605
      - BAY 19-8004: 1

Experts

1.	Benschop, N: 1 article (01/2003)
2.	Gauw, S A: 1 article (01/2003)
3.	Grootendorst, D C: 1 article (01/2003)
4.	Hiemstra, P S: 1 article (01/2003)
5.	Rabe, K F: 1 article (01/2003)
6.	Sterk, P J: 1 article (01/2003)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2003 - "Sputum cell counts were not different following placebo and BAY 19-8004 treatment in asthma and COPD patients (p>0.2). " 01/01/2003 - "In conclusion, 1 week of treatment with the selective PDE4 inhibitor BAY 19-8004 does not affect FEV1 and sputum cell numbers in patients with asthma or COPD. " 01/01/2003 - "Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD)." 01/01/2003 - "We examined the effect of 1 week treatment with BAY 19-8004 (5 mg once daily), a novel orally administered PDE4 inhibitor, on trough FEV1 and markers of inflammation in induced sputum in patients with asthma or chronic obstructive pulmonary disease (COPD). "
2.	Inflammation (Inflammations) 01/01/2003 - "Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD)." 01/01/2003 - "We examined the effect of 1 week treatment with BAY 19-8004 (5 mg once daily), a novel orally administered PDE4 inhibitor, on trough FEV1 and markers of inflammation in induced sputum in patients with asthma or chronic obstructive pulmonary disease (COPD). "
3.	Asthma (Bronchial Asthma) 01/01/2003 - "Sputum cell counts were not different following placebo and BAY 19-8004 treatment in asthma and COPD patients (p>0.2). " 01/01/2003 - "In conclusion, 1 week of treatment with the selective PDE4 inhibitor BAY 19-8004 does not affect FEV1 and sputum cell numbers in patients with asthma or COPD. " 01/01/2003 - "Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD)." 01/01/2003 - "We examined the effect of 1 week treatment with BAY 19-8004 (5 mg once daily), a novel orally administered PDE4 inhibitor, on trough FEV1 and markers of inflammation in induced sputum in patients with asthma or chronic obstructive pulmonary disease (COPD). "

Related Drugs and Biologics

1.	Type 4 Cyclic Nucleotide Phosphodiesterases
2.	Phosphodiesterase 4 Inhibitors